PORTON DOWN, England - In the news release, “Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK’s Veterinary Laboratories Agency” issued on 30 Jun 2009 13:17 GMT, by Enigma Diagnostics Limited over PR Newswire, we are advised by a representative of the company that a second footnote has been added at the end of the fourth paragraph. The note references the following link: enigmadiagnostics.com/template2.php?page=news.php&m=4
Complete, corrected release follows:
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory).
BVD is considered to be one of the main threats to cattle (1), affecting the majority of herds in the UK. It is closely related to classical swine fever virus, a serious disease of pigs, and to border disease virus, which infects sheep.
The Enigma FL instrument was used to analyse more than 100 blood samples that had already been screened by antigen ELISA and a laboratory-based RT-PCR for the presence of the BVD virus. Approximately half of the samples were proved BVDV positive by the laboratory-based PCR. With the level of concordance between the two tests being above 97%, this confirmed the Enigma FL system can produce laboratory-standard results with a high degree of confidence.
The Enigma FL has been designed for easy operation. Tests are provided in a single-use cartridge that can be stored at room temperature. The Enigma FL provides a PCR result in less than one hour, a timescale needed to allow field-based & pen-side diagnosis. On-site testing removes delays from transport of samples to the laboratory, which can often take days. The system requires minimal training and its utility for “pen-side” testing for BVD has already been demonstrated.(2)
John McKinley, Chairman and CEO of Enigma, stated: “The Enigma Diagnostics tests could be deployed for the related viral diseases, such as classical swine fever, with minor modifications. The system itself is broadly applicable to many other veterinary pathogens, such as TB in cattle, bacterial infections and other viral infections, such as foot and mouth disease and avian influenza. Allowing vets to use advanced molecular diagnosis in the field will enhance their efficiency in managing endemic and exotic disease outbreaks identifying diseased animals and as importantly, non-infected ones and improve their surveillance capability.”
(1) www.rvc.ac.uk/BVD/documents/BVD_Disease.ppt (2) enigmadiagnostics.com/template2.php?page=news.php&m=4 Contacts UK Contact: Enigma Diagnostics Deborah Cordingley deborah.cordingley@enigmadiagnostics.com +44-1980-590131 US Contact: Richard Lewis Communications, Inc. +1-212-827-0020 Gregory Tiberend - Media gtiberend@rlcinc.com Cecelia Heer - Investors cheer@rlcinc.com
About Enigma Diagnostics Limited
Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.
Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.
The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma’s commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive licence from the Defence Science and Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma’s R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
For more information visit www.enigmadiagnostics.com.
Source: Enigma Diagnostics Limited
UK Contact: Deborah Cordingley, +44-1980-590131, or deborah.cordingley at enigmadiagnostics.com of Enigma Diagnostics; US Contact: Gregory Tiberend - Media, gtiberend at rlcinc.com, or Cecelia Heer - Investors, cheer at rlcinc.com, both of Richard Lewis Communications, Inc., +1-212-827-0020, for Enigma Diagnostics
Related Press Releases
Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.July 15th, 2009 PORTON DOWN, England -
Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS). The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis.
Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories AgencyJune 29th, 2009 PORTON DOWN, England -
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory). BVD is considered to be one of the main threats to cattle (1), affecting the majority of herds in the UK.
Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics MarketJune 22nd, 2009 LONDON - The European diabetes diagnostics market is poised for expansion with segments such as self-monitoring and point-of-care (POC) tests offering tremendous growth potential. Heightened efforts to generate awareness about diabetes and related diagnostic tests are a key driver in market development.
Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent OfficeJune 15th, 2009 PORTON DOWN, England - Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today it was issued European Patent EP1044283, which covers the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies. Becton, Dickinson and Company (BD) had filed a claim in opposition to this patent which was rejected by the European Patent Office at a proceeding in Munich on May 28.
Sirius Genomics Announces 2009 Board of DirectorsJune 7th, 2009 VANCOUVER - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that it has elected its 2009 Board of Directors at its recent Annual General Meeting. The six-member Board consists of: Dr.
Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic AssaysJune 1st, 2009 SAN RAMON, California - BioGenex, a developer of innovative instruments and reagents for automated slide based staining systems for molecular diagnostics, announced today that Abbott has entered into a definitive agreement to extend the technology co-development and distribution agreement to market the Xmatrx(R) platform for the automation of Abbott's extensive FISH product line. Under the terms of the agreement Abbott customers will have the option to run IHC and ISH on the Xmatrx and BioGenex customers to run FISH on their system.
Copan and POCARED Diagnostics Partner to Enhance the Use of Liquid Based Microbiology and Introduce the Next Generation Microbiology SystemsMay 17th, 2009 BRESCIA, Italy - Alliance Aims to Develop Powerful Tools for Accurate and Rapid Microbiology Testing Leading to Improved Patient Outcomes
Under the partnership, the two companies will enhance the use of liquid based microbiology diagnostic products that incorporate Copan innovative collection and transport devices (like ESwab) for use in combination with POCARED's real-time quantification and identification platform. The Copan and POCARED partnership will also introduce a new level of automation and ease of use.
Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer TestingApril 28th, 2009 SYDNEY - To Receive Milestone Payments from Quest Diagnostics
Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after successfully achieving key research and development goals.
Growing Competition Leading to Strategic Consolidations: Hear Frost & Sullivan on the European Diagnostics SpaceApril 28th, 2009 LONDON - The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European In-Vitro Diagnostics Market to be held on Thursday, 7th May 2009, at 2 p.m. GMT. (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
The global In-Vitro Diagnostics (IVD) market has been witnessing sporadic growth in the past five years with the European sector contributing a third to the total market.
Mycosafe and ViruSure: Two Austrian Biosafety Companies Expand to AsiaMarch 18th, 2009 VIENNA, Austria and SINGAPORE - Mycoplasma biosafety specialist Mycosafe Diagnostics GmbH and virus and
prion biosafety company ViruSure GmbH - both based in Vienna, Austria - today
announced at BioMedical Asia 2009 that they are to establish a second site in
Singapore as part of a joint venture. This move will ensure that both
companies are in an ideal position to offer the biosafety expertise and
laboratory services so urgently required in the rapidly-expanding
biopharmaceutical and biotechnology industry in Asia.
Related News
Continucare says it bought sleep study testing facility operator for an undisclosed amountAugust 13th, 2009 Continucare buys Professional Sleep DiagnosticsMIAMI — Continucare Corp. said Thursday it bought Professional Sleep Diagnostics Inc., a company that operates 13 sleep diagnostic centers, for an undisclosed amount.
A look at the 2009 Ford Flex Limited AWDJune 3rd, 2009 A look at the 2009 Ford Flex Limited AWD2009 Ford Flex Limited AWD
BASE PRICE: $28,550 for SE; $32,325 for SEL with two-wheel drive; $34,175 for SEL with all-wheel drive; $34,960 for Limited with two-wheel drive; $36,810 for Limited with all-wheel drive. AS TESTED: $44,150.
Good night's sleep boosts immunity, protects against parasitesJanuary 10th, 2009 LONDON - A sound sleep boosts immunity and protects against parasite infestation, according to a study. Brian Preston from the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, led an international team of researchers who tested the theory that sleep boosts immunity.
Century-old enigma of prehistoric marine mass grave solvedJune 9th, 2009 WASHINGTON - A new study has solved a century-old enigma of the origin of a prehistoric marine massive bonebed in southern California, US. The study was led by Nick Pyenson, a post-doctoral fellow in the UBC (University of British Columbia) Department of Zoology.
A look at the 2010 Subaru ForesterAugust 5th, 2009 A look at the 2010 Subaru Forester2010 Subaru Forester 2.5XT Limited
BASE PRICE: $20,295 for 2.5X; $22,795 for 2.5X Premium; $25,995 for 2.5X Limited; $26,495 for 2.5XT Premium; $28,495 for 2.5XT Limited. AS TESTED: $29,694.
Covidien closes sale of sleep diagnostic assets to Embla SystemsSeptember 21st, 2009 Covidien closes sale of sleep productsNEW YORK — Medical device maker Covidien said Monday it completed the sale of its sleep diagnostics assets to Embla Systems. Financial details of the previously announced deal were undisclosed.
Analyst sees Limited beating expectations in 2Q, but doesn't see recovery until later in yearAugust 19th, 2009 Analyst sees Limited Brands recovery in 4QNEW YORK — Specialty retailer Limited Brands Inc. reports fiscal second-quarter results after the market closes Wednesday, but one analyst said she doesn't expect markedly improved results until the fourth quarter.
Pfizer to make tender offer to increase stake in Pfizer LimitedApril 13th, 2009 MUMBAI - Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, today announced that it will make a tender offer to acquire a 33.77 per cent stake in Pfizer Limited from public shareholders at a price of Rs. 675.00 per share.
Novel TB test may provide results quickly, efficientlyMay 8th, 2009 WASHINGTON - A scientist has developed a new diagnostic test for TB, called Xpert MTB/RIF, which can provide results quickly and efficiently. The test, developed by Dr.
2 injured in small plane crash near NJ's Teterboro AirportAugust 21st, 2009 2 injured in small plane crash near TeterboroTETERBORO, N.J. — New Jersey State Police say a small plane crashed near Teterboro Airport and the two men on board, the pilot and a passenger, walked away from the fiery wreckage.
